Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

What was studied

AUGMENT was a late-stage trial. It compared lenalidomide plus rituximab, called R2, with rituximab plus placebo. The people had indolent non-Hodgkin lymphoma that came back or did not respond. They were assigned by chance, 1:1. This report gives long-term follow-up. It also gives subgroup results for follicular lymphoma. That includes people aged 70 and older.

What they found

358 people were assigned. 295 of them had follicular lymphoma. 66 of those were 70 or older. Median follow-up was 65.9 months. Progression-free and overall survival were better with R2. The hazard ratios were 0.50 and 0.59. Benefit and manageable safety also showed in follicular lymphoma. This included people 70 and older. Safety agreed with the first analysis.

What it means for patients

The team says follow-up of more than 5 years still supports R2. It is called a standard of care. This is for people with indolent lymphoma that came back or did not respond.

Why it is not certain yet

The investigator judged progression. Subgroups such as people 70 and older are smaller than the full group. The abstract does not give details of side effects.

Source

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.